{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3625","statisticalMethod":"Normal approximation"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.4","upperLimit":"56.2","value":"48.3"},{"groupId":"OG001","lowerLimit":"31.3","upperLimit":"52.9","value":"42.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"84"}],"units":"Participants"}],"description":"Overall Survival (OS) is defined as the time from the date of randomization to the date of death or last contact","dispersionType":"95% Confidence Interval","groups":[{"description":"plitidepsin + dexamethasone combination\n\nplitidepsin + dexamethasone: plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.","id":"OG000","title":"Plitidepsin+Dexamethasone"},{"description":"dexamethasone single agent\n\ndexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.","id":"OG001","title":"Dexamethasone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From randomization to the death due to any cause,assessed up to 12 months","title":"Percentage of Participants With Overall Survival at 12 Months","type":"SECONDARY","unitOfMeasure":"percentage of participants"}